Details About Generic Salt ::  Insulin2

Main Medicine Class:: Antidiabetic   

(IN-suh-lin)

Insulin Aspart

NovoLog

Injection

100 IU/mL human insulin aspart (rDNA)

Insulin Glargine

Lantus

Injection

100 IU(3.6378 mg) insulin glargine

Insulin Lispro

Humalog

Injection

100 IU/mL Human insulin lispro (rDNA)

Humalog Mix 75/25

Injection

100 IU/mL Human insulin lispro (rDNA)

Humalog Mix 50/50

Injection

100 IU/mL Human insulin lispro (rDNA)

Class: Antidiabetic

 Indications

Insulin Aspart

Treatment of patients with diabetes mellitus for the control of hyperglycemia; however, because of rapid onset and short duration of action, insulin aspart should normally be used in regimens that include an intermediate- or long-acting insulin.

Insulin Glargine

Treatment of patients with diabetes mellitus who require long-acting insulin for control of hypoglycemia.

Insulin Lispro

Treatment of patients with diabetes mellitus for control of hyperglycemia. In patients with type 1 diabetes, use in regimens that include a longer-acting insulin. In patients with type 2 diabetes, may be used without longer-acting insulin when used concurrently with sulfonylureas.

 Contraindications During episodes of hypoglycemia; hypersensitivity to any component.

 Route/Dosage

Insulin Aspart

Adults: SC Individualized; determined by health care provider in accordance with patient’s needs (usual requirement 0.5 to 1 units/kg/day). Insulin pump When used in the external insulin infusion pump, the initial pump programming is based on the total insulin dose of the previous regimen. Although there is interpatient variability, approximately 50% of the total dose is given as meal-related boluses, and the remainder as basal infusion.

Insulin Glargine

Adults and Children at least 6 yr: SC Once daily at bedtime, dose determined by close monitoring under medical supervision during change from a treatment regimen with an intermediate- or long-acting insulin.

Insulin Lispro

NA

Type 1 Diabetes

Adults: SC Variable; determined by health care professional.

Type 2 Diabetes

Adults and Children older than 3 yr (in combination with sulfonylureas): SC Variable; determined by health care professional.

Insulin Lispro Mix

Adults: SC Variable; determined by health care professional.

 Interactions

Oral Contraceptives, Corticosteroids, Estrogens, Isoniazid, Niacin, Phenothiazines, Thyroid Hormone: May decrease hypoglycemic effects of insulin lispro.

Alcohol, Angiotensin-Converting Enzyme Inhibitors, Beta Blockers, MAO Inhibitors, Oral Hypoglycemic Agents, Pancreatic Function Inhibitors (eg, Octreotide, Salicylates, Sulfa Antibiotics): May increase hypoglycemic effects of insulin lispro. Beta blockers may mask the symptoms of hypoglycemia in some patients.

 Lab Test Interferences None well documented.

 Adverse Reactions

DERMATOLOGIC: Lipodystrophy (from repeated insulin injection into same site). METABOLIC: Hypoglycemia; hypokalemia. OTHER: Hypersensitivity reaction (eg, rash, shortness of breath, fast pulse, sweating, hypotension, anaphylaxis, angioedema); local reactions (eg, redness, swelling, and itching at injection site).

 Precautions

Pregnancy: Category B (insulin lispro); Category C (insulin aspart, insulin glargine). Lactation: Undetermined. Children:

Insulin aspart- Safety and efficacy not established. Insulin Glargine- Safety and efficacy not established in children less than 6 yr with type 1 diabetes. Insulin Lispro- In combination with sulfonylureas, safety and efficacy not established in children up to 3 yr. Insulin Lispro Mix- Safety and efficacy not established in children up to 18 yr.

Changing Insulin: Changes in purity, strength, brand, type, species source, or method of manufacture (rDNA vs animal source) of insulin may necessitate dosage adjustment. Make changes cautiously under medical supervision.

Renal/Hepatic Impairment: Insulin lispro dose may need to be reduced.

Hypoglycemia: May result from excessive insulin dose, missed meals, increased work, or exercise without eating.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

• When mixing insulins, draw insulin lispro into syringe first. Administer immediately after mixing.
• Do not administer mixtures IV.
• Use only insulin syringes.
• Select appropriate injection site according to patient history and needs; rotate injection sites to prevent lipodystrophy. SC insulin lispro is absorbed most rapidly at abdominal injection sites, more slowly at sites on arms, and slowest at sites on anterior thigh.
• Administer insulin lispro 15 min before meals.
• Do not freeze. Do not use insulin lispro if previously frozen.
• Do not expose to extreme temperature or direct sunlight.

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Assess patient for signs of hypoglycemia (eg, anxiety, chills, confusion, cool and pale skin, drowsiness, excessive hunger, headache, irritability, nausea, rapid pulse, tremors).
• Observe patient for signs of hyperglycemia (eg, drowsiness, fruitlike breath odor, frequent urination, loss of appetite, thirst).
• Monitor blood glucose levels throughout course of therapy.
• Observe injection sites for signs of local hypersensitivity reaction, such as redness, itching, or burning.
• Notify health care provider if hypoglycemia or adverse reactions occur.
• If lipoatrophy or lipohypertrophy develop at injection site, use alternate sites or use purified insulin.
• Document injection sites used.

OVERDOSAGE: SIGNS & SYMPTOMS   Fatigue; weakness; nervousness; confusion; headache; diplopia; convulsions; psychosis; dizziness; unconsciousness; rapid or shallow respiration; numb or tingling mouth; hunger; nausea; skin pallor; moist or dry skin

 Patient/Family Education

• Teach name, dose, action, and side effects of insulin.
• Tell patient not to change brand, strength, type, or dose without health care provider’s knowledge.
• Dosage adjustments may be necessary when type of insulin is changed.
• Tell patient to consult health care provider for dosage changes during illness.
• Instruct patient to use same type and brand of syringe each time to prevent dosage errors.
• Explain potential long-term complications of diabetes and encourage regular general physical and eye examinations.
• Tell patient to report redness, swelling, or itching at injection site.
• Explain significance and importance of reporting the following side effects: visual changes; rash; infection that does not heal; increased thirst; increased urination; dry mouth; burning sensation in feet, legs, or hands; pain in legs after exercise; frequent episodes of low or high blood sugar levels.
• Show patient how to rotate injection sites to prevent scarring.
• Teach patient how to monitor blood glucose as directed.
• Identify source for obtaining medical ID (eg, Medi-Alert) and explain importance of information.
• Teach patient and family how to draw up and administer insulin.
• Demonstrate self-care techniques using insulin pump for patients.
• Emphasize importance of compliance with diet and exchange system for meals.
• Emphasize importance of regular exercise.
• Tell patient to carry source of sugar (eg, candy, sugar packets) to counteract hypoglycemia.

 

Drugs Class ::

(IN-suh-lin)

Insulin Aspart

NovoLog

Injection

100 IU/mL human insulin aspart (rDNA)

Insulin Glargine

Lantus

Injection

100 IU(3.6378 mg) insulin glargine

Insulin Lispro

Humalog

Injection

100 IU/mL Human insulin lispro (rDNA)

Humalog Mix 75/25

Injection

100 IU/mL Human insulin lispro (rDNA)

Humalog Mix 50/50

Injection

100 IU/mL Human insulin lispro (rDNA)

Class: Antidiabetic

Indications for Drugs ::

 Indications

Insulin Aspart

Treatment of patients with diabetes mellitus for the control of hyperglycemia; however, because of rapid onset and short duration of action, insulin aspart should normally be used in regimens that include an intermediate- or long-acting insulin.

Insulin Glargine

Treatment of patients with diabetes mellitus who require long-acting insulin for control of hypoglycemia.

Insulin Lispro

Treatment of patients with diabetes mellitus for control of hyperglycemia. In patients with type 1 diabetes, use in regimens that include a longer-acting insulin. In patients with type 2 diabetes, may be used without longer-acting insulin when used concurrently with sulfonylureas.

Drug Dose ::

 Route/Dosage

Insulin Aspart

Adults: SC Individualized; determined by health care provider in accordance with patient’s needs (usual requirement 0.5 to 1 units/kg/day). Insulin pump When used in the external insulin infusion pump, the initial pump programming is based on the total insulin dose of the previous regimen. Although there is interpatient variability, approximately 50% of the total dose is given as meal-related boluses, and the remainder as basal infusion.

Insulin Glargine

Adults and Children at least 6 yr: SC Once daily at bedtime, dose determined by close monitoring under medical supervision during change from a treatment regimen with an intermediate- or long-acting insulin.

Insulin Lispro

NA

Type 1 Diabetes

Adults: SC Variable; determined by health care professional.

Type 2 Diabetes

Adults and Children older than 3 yr (in combination with sulfonylureas): SC Variable; determined by health care professional.

Insulin Lispro Mix

Adults: SC Variable; determined by health care professional.

Contraindication ::

 Contraindications During episodes of hypoglycemia; hypersensitivity to any component.

Drug Precautions ::

 Precautions

Pregnancy: Category B (insulin lispro); Category C (insulin aspart, insulin glargine). Lactation: Undetermined. Children:

Insulin aspart- Safety and efficacy not established. Insulin Glargine- Safety and efficacy not established in children less than 6 yr with type 1 diabetes. Insulin Lispro- In combination with sulfonylureas, safety and efficacy not established in children up to 3 yr. Insulin Lispro Mix- Safety and efficacy not established in children up to 18 yr.

Changing Insulin: Changes in purity, strength, brand, type, species source, or method of manufacture (rDNA vs animal source) of insulin may necessitate dosage adjustment. Make changes cautiously under medical supervision.

Renal/Hepatic Impairment: Insulin lispro dose may need to be reduced.

Hypoglycemia: May result from excessive insulin dose, missed meals, increased work, or exercise without eating.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

DERMATOLOGIC: Lipodystrophy (from repeated insulin injection into same site). METABOLIC: Hypoglycemia; hypokalemia. OTHER: Hypersensitivity reaction (eg, rash, shortness of breath, fast pulse, sweating, hypotension, anaphylaxis, angioedema); local reactions (eg, redness, swelling, and itching at injection site).

Drug Mode of Action ::  

(IN-suh-lin)

Insulin Aspart

NovoLog

Injection

100 IU/mL human insulin aspart (rDNA)

Insulin Glargine

Lantus

Injection

100 IU(3.6378 mg) insulin glargine

Insulin Lispro

Humalog

Injection

100 IU/mL Human insulin lispro (rDNA)

Humalog Mix 75/25

Injection

100 IU/mL Human insulin lispro (rDNA)

Humalog Mix 50/50

Injection

100 IU/mL Human insulin lispro (rDNA)

Class: Antidiabetic

Drug Interactions ::

 Interactions

Oral Contraceptives, Corticosteroids, Estrogens, Isoniazid, Niacin, Phenothiazines, Thyroid Hormone: May decrease hypoglycemic effects of insulin lispro.

Alcohol, Angiotensin-Converting Enzyme Inhibitors, Beta Blockers, MAO Inhibitors, Oral Hypoglycemic Agents, Pancreatic Function Inhibitors (eg, Octreotide, Salicylates, Sulfa Antibiotics): May increase hypoglycemic effects of insulin lispro. Beta blockers may mask the symptoms of hypoglycemia in some patients.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Assess patient for signs of hypoglycemia (eg, anxiety, chills, confusion, cool and pale skin, drowsiness, excessive hunger, headache, irritability, nausea, rapid pulse, tremors).
• Observe patient for signs of hyperglycemia (eg, drowsiness, fruitlike breath odor, frequent urination, loss of appetite, thirst).
• Monitor blood glucose levels throughout course of therapy.
• Observe injection sites for signs of local hypersensitivity reaction, such as redness, itching, or burning.
• Notify health care provider if hypoglycemia or adverse reactions occur.
• If lipoatrophy or lipohypertrophy develop at injection site, use alternate sites or use purified insulin.
• Document injection sites used.

OVERDOSAGE: SIGNS & SYMPTOMS   Fatigue; weakness; nervousness; confusion; headache; diplopia; convulsions; psychosis; dizziness; unconsciousness; rapid or shallow respiration; numb or tingling mouth; hunger; nausea; skin pallor; moist or dry skin

Drug Storage/Management ::

 Administration/Storage

• When mixing insulins, draw insulin lispro into syringe first. Administer immediately after mixing.
• Do not administer mixtures IV.
• Use only insulin syringes.
• Select appropriate injection site according to patient history and needs; rotate injection sites to prevent lipodystrophy. SC insulin lispro is absorbed most rapidly at abdominal injection sites, more slowly at sites on arms, and slowest at sites on anterior thigh.
• Administer insulin lispro 15 min before meals.
• Do not freeze. Do not use insulin lispro if previously frozen.
• Do not expose to extreme temperature or direct sunlight.

Drug Notes ::

 Patient/Family Education

• Teach name, dose, action, and side effects of insulin.
• Tell patient not to change brand, strength, type, or dose without health care provider’s knowledge.
• Dosage adjustments may be necessary when type of insulin is changed.
• Tell patient to consult health care provider for dosage changes during illness.
• Instruct patient to use same type and brand of syringe each time to prevent dosage errors.
• Explain potential long-term complications of diabetes and encourage regular general physical and eye examinations.
• Tell patient to report redness, swelling, or itching at injection site.
• Explain significance and importance of reporting the following side effects: visual changes; rash; infection that does not heal; increased thirst; increased urination; dry mouth; burning sensation in feet, legs, or hands; pain in legs after exercise; frequent episodes of low or high blood sugar levels.
• Show patient how to rotate injection sites to prevent scarring.
• Teach patient how to monitor blood glucose as directed.
• Identify source for obtaining medical ID (eg, Medi-Alert) and explain importance of information.
• Teach patient and family how to draw up and administer insulin.
• Demonstrate self-care techniques using insulin pump for patients.
• Emphasize importance of compliance with diet and exchange system for meals.
• Emphasize importance of regular exercise.
• Tell patient to carry source of sugar (eg, candy, sugar packets) to counteract hypoglycemia.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.